Slide 1: Q2 2024 Results
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q2 2024 Results Q2 2024 Results Investor presentation Investor presentation July 18, 2024 July 18, 2024 Novartis Q2 Results | July 18, 2024 1
Slide 2: Disclaimer
Content Click below to navigate Disclaimer through the document Company overview This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,”
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Company Appendix References Company overview overview Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q2 Results | July 18, 2024 3
Slide 4: Novartis delivered a strong Q2 with double-digit sales growth and core margin expansion
Content Click below to navigate Novartis delivered a strong Q2 with double-digit sales growth and core margin expansion through the document Company overview Financial review Strong momentum in the business... ... and in the pipeline Conclusions Sales Core1 operating income Innovation highlights App
Slide 5: Q2 growth was broad-based, with strong contributions from established growth drivers and newer launches
GROWTH Content Click below to navigate Q2 growth was broad-based, with strong contributions from established growth drivers as well as newer launches through the document Company overview Financial review Q2 sales Conclusions Sales Growth vs PY Growth vs PY USD million USD million cc Appendix 1,898
Slide 6: Entresto delivered +28% growth in Q2, continuing its strong trajectory
GROWTH Content Click below to navigate Entresto® delivered +28% growth in Q2, continuing its strong trajectory through the document Company overview Financial review Sales evolution US weekly TRx1 Continued strong momentum in Q2 Conclusions USD m, % cc Total prescriptions (000) • US: +25%, fueled by
Slide 7: Cosentyx grew +22% fueled by new launches and expansion in core indications
GROWTH Content Click below to navigate Cosentyx® grew +22% fueled by new launches as well as expansion in core indications through the document Company overview Financial review Sales evolution Demand-driven growth across geographies Conclusions USD m, % cc • US: +34%, driven by volume US Ex-US • Ex
Slide 8: Kesimpta delivered +65% growth, with strong momentum globally
GROWTH Content Click below to navigate Kesimpta® delivered +65% growth, with strong momentum globally through the document Company overview Financial review Sales evolution Strong growth trajectory with increasing contribution ex-US Conclusions USD m, % cc • >100k patients treated worldwide, majorit
Slide 9: Kisqali grew +50% in mBC with leading NBRx share in US and ex-US
GROWTH Content Click below to navigate Kisqali® grew +50% in mBC with leading NBRx share in US and ex-US through the document Company overview Financial review Sales evolution US: +67% growth, gaining widespread adoption Conclusions USD m, % cc • Leading share in mBC NBRx at 47%1 US Ex-US • 7k HCPs
Slide 10: Pluvicto demonstrated continued steady growth of +44% vs PY
GROWTH Content Click below to navigate Pluvicto® demonstrated continued steady growth of +44% vs PY through the document Company overview ® Financial review Sales evolution Q2 performance driven by new patient starts Conclusions USD m, % cc • NBRx share in VISION population ~1/3; >50% in established
Slide 11: Strong Leqvio growth with increasing global adoption
GROWTH Content Click below to navigate Strong Leqvio® growth with increasing global adoption through the document Company overview Financial review Sales evolution US: Growth outpacing advanced lipid-lowering market1 Conclusions USD m, % cc • 4,235 facilities have ordered Leqvio® (+8% vs PQ; +48% vs
Slide 12: Scemblix momentum continued in Q2, with US market leadership in 3L+
GROWTH Content Click below to navigate Scemblix® momentum continued in Q2, with US market leadership in 3L+; 1L CML submission under FDA Real-Time Oncology Review (RTOR) through the document Company overview Financial review Sales evolution Strong demand in core indication of 3L+ CML Conclusions USD
Slide 13: Scemblix: Ph3 ASC4FIRST study in 1L CML
INNOVATION Content Click below to navigate Scemblix®: Ph3 ASC4FIRST study demonstrated superior efficacy with a favorable safety and tolerability profile vs SoC TKIs in 1L CML through the document Company overview Financial review Efficacy Safety and tolerability Conclusions • Superior MMR rates vs
Slide 14: Fabhalta US PNH launch off to an encouraging start
GROWTH Content Click below to navigate Fabhalta®1 US PNH launch off to an encouraging start; ex-US approvals received in EU, China and Japan through the document Company overview Financial review Increasing intent to prescribe, reflecting compelling product profile Conclusions Appendix US launch upd
Slide 15: Atrasentan: Ph3 ALIGN-IgAN proteinuria reduction
INNOVATION Content Click below to navigate Atrasentan: Ph3 ALIGN-IgAN study demonstrated 36%1 proteinuria reduction relative to placebo through the document Company overview Financial review Conclusions Appendix References Novartis Q2 Results | July 18, 2024 15 Novartis Q2 Results | July 18, 2024 15
Slide 16: Iptacopan: Ph3 APPEAR-C3G proteinuria reduction
INNOVATION Content Click below to navigate Iptacopan: Ph3 APPEAR-C3G study demonstrated 35%1 proteinuria reduction relative to placebo through the document Company overview Financial review Study design Proteinuria reduction in C3G patients at month 6 Conclusions Primary endpoint End of analysis stu
Slide 17: Expect to continue our innovation momentum in H2
INNOVATION Content Click below to navigate Expect to continue our innovation momentum in H2 through the document Company overview Financial review 2024 selected key events (expected) Conclusions H1 2024 H2 2024 Q2 status update Regulatory Fabhalta® PNH EU, JP EU, JP and China approval in Q2 Appendix
Slide 18: Financial review and 2024 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Financial review Appendix References Financial review and 2024 guidance and 2024 guidance Harry Kirsch Harry Kirsch Chief Financial Officer Chief Financial Officer Novartis Q2 Results | July 18, 2024 1
Slide 19: Q2 net sales grew +11% cc with core operating income up +19% cc
FINANCIAL PROFILE Content Click below to navigate Q2 net sales grew +11% cc with core operating income up +19% cc1 through the document Company overview Financial review Continuing Operations1,2 Q2 Q2 Change vs PY H1 H1 Change vs PY Conclusions USD million 2023 2024 % USD % cc 2023 2024 % USD % cc A
Slide 20: 2024 with strong underlying growth dynamics in all quarters
FINANCIAL PROFILE Content Click below to navigate 2024 with strong underlying growth dynamics in all quarters; Q3 growth lower due to PY one-timers through the document Company overview Financial review Conclusions Appendix References Novartis Q2 Results | July 18, 2024 20 Novartis Q2 Results | July
Slide 21: Raising 2024 core operating income guidance
FINANCIAL PROFILE Content Click below to navigate Raising 2024 core operating income guidance1 Expected, barring unforeseen events; growth vs PY in cc1 through the document Company overview Financial review Conclusions Net sales Core operating income Appendix expected to grow expected to grow high s
Slide 22: Continuing our shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate Continuing our shareholder-friendly capital allocation strategy through the document Company overview Financial review Conclusions Investing in the business Returning capital to shareholders Appendix Investments in organic business Consistently growi
Slide 23: Expected currency impact for full year 2024
FINANCIAL PROFILE Content Click below to navigate Expected currency impact for full year 2024 through the document Company overview Financial review Conclusions Appendix References Novartis Q2 Results | July 18, 2024 23 Novartis Q2 Results | July 18, 2024 23
Slide 24: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q2 Results | July 18, 2024 24
Slide 25: Continued momentum in Q2, with net sales up +11% and core margin approaching 40%
Content Click below to navigate through the document Company overview Continued momentum in Q2, with net sales up +11% and core operating income margin Financial review Conclusions approaching 40% Appendix References Strong commercial execution across geographies and growth brands, supporting bottom
Slide 26: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials References Appendix Appendix Novartis Q2 Results | July 18, 2024 26
Slide 27: Our pipeline projects at a glance
INNOVATION Content Click below to navigate Our pipeline projects at a glance through the document Company overview Financial review Phase 1/2 Phase 3 Registration Total Conclusions Oncology 25 9 5 39 Appendix Solid tumors 18 4 4 26 Innovation: Pipeline overview Hematology 7 5 1 13 Financial performa
Slide 28: Novartis pipeline in Phase 1
INNOVATION Content Click below to navigate Novartis pipeline in Phase 1 17 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFT383 DFT383 CTNS gene delivery Cystinosis pre/post kidney tran
Slide 29: Novartis pipeline in Phase 2
INNOVATION Content Click below to navigate Novartis pipeline in Phase 2 21 lead indications through the document Lead indication Company overview Oncology Immunology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) CFZ533 iscalimab CD40 inhibitor Sjögren’s Solid tumors Financial r
Slide 30: Novartis pipeline in Phase 3
INNOVATION Content Click below to navigate Novartis pipeline in Phase 3 7 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis, ped
Slide 31: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration 1 lead indication through the document Company overview Oncology Code Name Mechanism Indication(s) Solid tumors Financial review LEE011 Kisqali® CDK4/6 Inhibitor HR+/HER2- BC (adj) INC424 Jakavi® JAK1/2 inhibitor Acute GVHD
Slide 32: Novartis submission schedule: New Molecular Entities
INNOVATION Content Click below to navigate Novartis submission schedule New Molecular Entities: Lead and supplementary indications through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions atrasentan pelacarsen ia
Slide 33: Novartis submission schedule: Existing brands
INNOVATION Content Click below to navigate Novartis submission schedule Supplementary indications for existing brands through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions Lutathera® Cosentyx® Cosentyx® Aimovi
Slide 34: Net debt increased by USD 8.6bn mainly due to the annual dividend and M&A
Content Click below to navigate Net debt increased by USD 8.6bn mainly due to the annual dividend and M&A, partially offset by FCF through the document Company overview Financial review USD bn Conclusions -8.6 Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials R
Slide 35: IR Clinical Studies
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience
Slide 36: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Cardiovascular, Cardiovascular, Financial performance Innovation: Clinical trials Renal and Metabolic > C ardiovascular, Renal Renal and Metabolic and Metabolic >
Slide 37: atrasentan - ETA receptor antagonist
Content Click below to navigate atrasentan - ETA receptor antagonist through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 380 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 38: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 39: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor through the document Company overview NCT03955445 (CLNP023B12001B) NCT04817618 APPEAR-C3G (CLNP023B12301) Financial review Indication C3 glomerulopathy (C3G) Indication C3 glomerulopathy Phase Phase 2 Phase Phase 3 C
Slide 40: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 41: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT04652726 ORION-16 (CKJX839C12301) NCT04659863 ORION-13 (CKJX839C12302) Financial review Indication Hyperlipidemia, pediatrics Indication Hyperlipidemia
Slide 42: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) NCT05763875 V-Mono (CKJX839D12304) Financial review Indication CVRR (Primary prevention) Indication CVRR (Primary
Slide 43: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Content Click below to navigate pelacarsen - Antisense oligonucleotide (ASO) through the document targeting Lp(a) Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 44: XXB750 - NPR1 agonist
Content Click below to navigate XXB750 - NPR1 agonist XXB750 - NPR1 agonist through the document Company overview NCT05562934 (CXXB750B12201) NCT06142383 (CXXB750A12201) Financial review Indication Hypertension Indication Heart failure Phase Phase 2b Phase Phase 2 Conclusions Patients 170 Patients 7
Slide 45: zigakibart - Anti-APRIL
Content Click below to navigate zigakibart - Anti-APRIL through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 292 Appendix Primary Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months
Slide 46: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal Immunology and Metabolic > I mmunology > N euroscience > O ncology > I n-mar
Slide 47: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05767034 REPLENISH (CAIN457C22301) NCT04930094 GCAPTAIN (CAIN457R12301) Financial review Indication Polymyalgia rheumatica Indication Giant cell arteritis Phase Phase 3
Slide 48: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT03217422 AMBER (CVAY736B2201) NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Autoimmune
Slide 49: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05349214 NEPTUNUS-2 (CVAY736A2302) NCT05350072 NEPTUNUS-1 (CVAY736A2301) Financial review Indication Sjögre
Slide 50: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 51: LNA043 - ANGPTL3 agonist
Content Click below to navigate LNA043 - ANGPTL3 agonist through the document Company overview NCT04864392 ONWARDS (CLNA043A12202) Financial review Indication Knee osteoarthritis Phase Phase 2 Conclusions Patients 576 Primary Change from baseline in the cartilage thickness of the medial compartment
Slide 52: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05030311 REMIX-1 (CLOU064A2301) NCT05032157 REMIX-2 (CLOU064A2302) Financial review Indication Chronic spontaneous urticaria Indication Chronic spontaneous urticaria Pha
Slide 53: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Sco
Slide 54: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal Neuroscience and Metabolic > I mmunology > N euroscience > O ncology > I n
Slide 55: Mayzent - S1P1,5 receptor modulator
Content Click below to navigate Mayzent® - S1P1,5 receptor modulator through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple sclerosis, pediatrics Phase Phase 3 Conclusions Patients 120 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 56: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple sclerosis Indication Multiple sclerosis Phase Phase 3 Phase
Slide 57: Zolgensma - SMN1 gene replacement therapy
Content Click below to navigate Zolgensma® - SMN1 gene replacement therapy Zolgensma® - SMN1 gene replacement therapy through the document Company overview NCT05089656 STEER (COAV101B12301) NCT05386680 STRENGTH (COAV101B12302) Financial review Indication Spinal muscular atrophy (IT administration) I
Slide 58: Iptacopan - CFB inhibitor
Content Click below to navigate Iptacopan - CFB inhibitor through the document Company overview CLNP023Q12301 Financial review Indication Generalized Myasthenia Gravis Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 Appendix in Myasthenia Gravis Activity of Outcome Mea
Slide 59: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal Oncology and Metabolic > I mmunology > N euroscience > O ncology > I n-market
Slide 60: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 VAYHIT2 (CVAY736Q12301) Financial review Indication 1L Immune
Slide 61: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating w
Slide 62: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) Financial review Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Conclusions Patients 50 Primary Percentage of participants with complete TMA response wi
Slide 63: Pluvicto - Radioligand therapy target PSMA
Content Click below to navigate Pluvicto® - Radioligand therapy target PSMA Pluvicto® - Radioligand therapy target PSMA through the document Company overview NCT04689828 PSMAfore (CAAA617B12302) NCT04720157 PSMAddition (CAAA617C12301) Financial review Indication Metastatic castration-resistant prost
Slide 64: Rydapt - Multi-targeted kinase inhibitor
Content Click below to navigate Rydapt® - Multi-targeted kinase inhibitor through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 65: Scemblix - BCR-ABL inhibitor
Content Click below to navigate Scemblix® - BCR-ABL inhibitor through the document Company overview NCT04971226 ASC4FIRST (CABL001J12301) Financial review Indication Chronic myeloid leukemia, 1st line Phase Phase 3 Conclusions Patients 402 Primary Major Molecular Response (MMR) at week 48 Appendix O
Slide 66: Vijoice - PI3Ki
Content Click below to navigate Vijoice® - PI3Ki through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Outcome Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and
Slide 67: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview In-market Brands In-market Brands Financial performance Innovation: Clinical trials & Global Health > C ardiovascular, Renal & Global Health and Metabolic > I mmu
Slide 68: Beovu - VEGF Inhibitor
Content Click below to navigate Beovu® - VEGF Inhibitor through the document Company overview NCT04278417 CONDOR (CRTH258D2301) Financial review Indication Diabetic retinopathy Phase Phase 3 Conclusions Patients 694 Primary Change from Baseline in BCVA Appendix Outcome Innovation: Pipeline overview
Slide 69: cipargamin - PfATP4 inhibitor
Content Click below to navigate cipargamin - PfATP4 inhibitor through the document Company overview NCT04675931 KARISMA (CKAE609B12201) Financial review Indication Malaria severe Phase Phase 2 Conclusions Patients 252 Primary Percentage of participants achieving at least 90% reduction in Plasmodium
Slide 70: Coartem - Artemisinin combination therapy
Content Click below to navigate Coartem® - Artemisinin combination therapy through the document Company overview NCT04300309 CALINA (CCOA566B2307) Financial review Indication Malaria, uncomplicated (<5kg patients) Phase Phase 3 Conclusions Patients 44 Primary Artemether Cmax Appendix Outcome Innovat
Slide 71: ganaplacide/lumefantrine - Non-artemisinin plasmodium falciparum inhibitor
Content Click below to navigate ganaplacide/lumefantrine - Non-artemisinin through the document plasmodium falciparum inhibitor Company overview NCT05842954 KALUMA (CKLU156A12301 ) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1500 Primary PCR-corrected adequa
Slide 72: References 1/2
Content Click below to navigate References 1/2 through the document Company overview Entresto® (slide 6 references) Financial review 1 IQVIA National Prescription Audit. 2 AHA/ACC/HFSA/ESC. Conclusions 3 Extension of regulatory data protection to November 2026 in EU based on approval of pediatric in
Slide 73: References 2/2
Content Click below to navigate References 2/2 through the document Company overview Leqvio® (slide 11 references) Financial review 1 Includes PCSK9 mAbs and bempedoic acid. 2 Niu X et al. Poster presented at: National Lipid Association Scientific Sessions 2024; May 30-June 2, 2024. Las Vegas, NV. P